Single-dose tolerability, pharmacokinetics, and pharmacodynamics of etamicastat (BIA 5-453), a new dopamine β-hydroxylase inhibitor, in healthy subjects

Journal of Clinical Pharmacology

Volumn 52, Issue 2, 2012, Pages 156-170

  Rocha, José Francisco ^a   Vaz Da Silva, Manuel ^a   Nunes, Teresa ^a   Igreja, Bruno ^a   Loureiro, Ana I ^a   Bonifácio, Maria João ^a   Wright, Lyndon C ^a   Falcão, Amílcar ^b   Almeida, Luis ^c   Soares Da Silva, Patricio ^a,d  

^a DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

^b 4Health Ltd   (Portugal)

^c UNIVERSITY OF AVEIRO   (Portugal)

^d University of Porto   (Portugal)

Author keywords

dopamine hydroxylase; Etamicastat; pharmacodynamics; pharmacokinetics; tolerability

Indexed keywords

AMINOACYLTRANSFERASE; BIA 5453; BIA 5961; DOPAMINE BETA MONOOXYGENASE; DRUG METABOLITE; ETAMICASTAT; PLACEBO; UNCLASSIFIED DRUG; ARYLAMINE ACETYLTRANSFERASE; BENZOPYRAN DERIVATIVE; IMIDAZOLE DERIVATIVE; ISOENZYME; N-ACETYLTRANSFERASE 1; NAT2 PROTEIN, HUMAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD CHEMISTRY; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACETYLATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; ELECTROCARDIOGRAM; ENZYME INHIBITION; GENETIC VARIABILITY; HEADACHE; HEMATOLOGICAL PARAMETERS; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; ORTHOSTATIC HYPOTENSION; PHARMACOGENOMICS; PHASE 1 CLINICAL TRIAL; PHENOTYPE; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; URINALYSIS; VITAL SIGN; ACETYLATION; ADOLESCENT; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; GENETICS; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ACETYLATION; ADOLESCENT; ADULT; ARYLAMINE N-ACETYLTRANSFERASE; BENZOPYRANS; DOPAMINE BETA-HYDROXYLASE; DOUBLE-BLIND METHOD; HEALTHY VOLUNTEERS; HUMANS; IMIDAZOLES; ISOENZYMES; MALE; MIDDLE AGED; PHENOTYPE; YOUNG ADULT;

EID: 84856588920     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010390805     Document Type: Article

References (31)

1. Esler M, Kaye D. Sympathetic nervous system activation in essential hypertension, cardiac failure and psychosomatic heart disease. J Cardiovasc Pharmacol. 2000 ; 35 (7). S1 - S7
2. Grassi G, Bolla G, Quarti-Trevano F, Arenare F, Brambilla G, Mancia G. Sympathetic activation in congestive heart failure: reproducibility of neuroadrenergic markers. Eur J Heart Fail. 2008 ; 10: 1186-1191
3. Grassi G, Seravalle G, Quarti-Trevano F. The "neuroadrenergic hypothesis" in hypertension: current evidence. Exp Physiol. 2010 ; 95: 581-586
4. Lee CS, Tkacs NC. Current concepts of neurohormonal activation in heart failure: mediators and mechanisms. AACN Adv Crit Care. 2008 ; 19: 364-385
5. Mancia G, Grassi G, Giannattasio C, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension. 1999 ; 34 (4). 724-728 (Pubitemid 29501288)
6. Parmley WW. Neuroendocrine changes in heart failure and their clinical relevance. Clin Cardiol. 1995 ; 18: 440-445
7. Pfeffer MA, Stevenson LW. Beta-adrenergic blockers and survival in heart failure. N Engl J Med. 1996 ; 334: 1396-1397 (Pubitemid 26152721)
8. Stanley WC, Li B, Bonhaus DW, et al. Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase. Br J Pharmacol. 1997 ; 121: 1803-1809 (Pubitemid 27343414)
9. Hegde SS, Friday KF. Dopamine-beta-hydroxylase inhibition: a novel sympatho-modulatory approach for the treatment of congestive heart failure. Curr Pharm Des. 1998 ; 4: 469-479 (Pubitemid 28536753)
10. Soares-da-Silva P. Evidence for a non-precursor dopamine pool in noradrenergic neurones of the dog mesenteric artery. Naunyn Schmiedebergs Arch Pharmacol. 1986 ; 333: 219-223
11. Soares-da-Silva P. A comparison between the pattern of dopamine and noradrenaline release from sympathetic neurones of the dog mesenteric artery. Br J Pharmacol. 1987; 90: 91-98
12. Gomes P, Soares-da-Silva P Cardiovascular Hormone Systems: From Molecular Mechanisms to Novel Therapeutics. Baden M, ed. Weinheim, Germany: Wiley-VCH ; 2008: 251-293.
13. Jose PA, Eisner GM, Felder RA. Role of dopamine receptors in the kidney in the regulation of blood pressure. Curr Opin Nephrol Hypertens. 2002 ; 11: 87-92 (Pubitemid 34053343)
14. Goldstein M, Anagnoste B, Lauber E, McKeregham MR. Inhibition of dopamine-beta-hydroxylase by disulfiram. Life Sci. 1964 ; 3: 763-767
15. Lippmann W, Lloyd K. Dopamine-hydroxylase inhibition by dimethyldithiocarbamate and related compounds. Biochem Pharmacol. 1969 ; 18: 2507-2516
16. Hidaka H. Fusaric (5-butylpicolinic) acid, an inhibitor of dopamine beta-hydroxylase, affects serotonin and noradrenaline. Nature. 1971 ; 231: 54-55
17. Johnson GA, Boukma SJ, Kim EG. In vivo inhibition of dopamine beta-hydroxylase by 1-phenyl-3-(2-thiazolyl)-2-thiourea (U-14,624). J Pharmacol Exp Ther. 1970 ; 171: 80-87
18. Bonifácio MJ, Igreja B, Wright L, Soares-Da-Silva P. Kinetic studies on the inhibition of dopamine-beta-hydroxylase by BIA 5-453 [abstract]. pA2 Online. 2009 ; 7: 050P
19. Beliaev A, Learmonth DA, Soares-da-Silva P. Synthesis and biological evaluation of novel, peripherally selective chromanyl imidazolethione-based inhibitors of dopamine beta-hydroxylase. J Med Chem. 2006 ; 49: 1191-1197 (Pubitemid 43221665)
20. Igreja B, Loureiro AI, Fernandes-Lopes C, et al. Interspecies differences in pharmacodynamic and disposition of BIA 5-453, a novel dopamine-beta- hydroxylase inhibitor [abstract]. Drug Metabolism Rev. 2009 ; 40 (suppl 1). 39-40
21. Igreja B, Wright L, Soares-da-Silva P. Sustained antihypertensive effects of a selective peripheral dopamine-β-hydroxylase inhibitor [abstract]. Hypertension. 2007 ; 50: e133
22. Igreja B, Wright L, Soares-da-Silva P. Long-term lowering of blood pressure levels in the SHR by selective peripheral inhibition of dopamine-β-hydroxylase with BIA 5-453 [abstract]. pA2 Online. 2008 ; 6: 087P
23. Wright L, Soares-da-Silva P. Long-term benefits of the selective peripheral dopamine-β-hydroxylase inhibitor BIA 5-453 in heart failure [abstract]. pA2 Online. 2008 ; 6: 088P
24. Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Healthy Adult Volunteers. Washington, DC: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER ; 2005 :
25. Fronhoffs S, Bruning T, Ortiz-Pallardo E, et al. Real-time PCR analysis of the N-acetyltransferase NAT1 allele *3, *4, *10, *11, *14 and *17 polymorphism in squamous cell cancer of head and neck. Carcinogenesis. 2001 ; 22: 1405-1412 (Pubitemid 32898697)
26. Li D, Jiao L, Li Y, et al. Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. Carcinogenesis. 2006 ; 27: 103-111 (Pubitemid 43025249)
27. Brocvielle H, Muret P, Goydadin AC, et al. N-acetyltransferase 2 acetylation polymorphism: prevalence of slow acetylators does not differ between atopic dermatitis patients and healthy subjects. Skin Pharmacol Appl Skin Physiol. 2003 ; 16: 386-392 (Pubitemid 37256074)
28. Rychlik-Sych M, Skretkowicz J, Gawronska-Szklarz B, Gornik W, Sysa-Jedrzejowska A, Skretkowicz-Szarmach K. Acetylation genotype and phenotype in patients with systemic lupus erythematosus. Pharmacol Rep. 2006 ; 58: 22-29
29. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Topic E14, International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use ; 2005 ; 2005..
30. Gough K, Hutchinson M, Keene O. Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party. Drug Inf J. 1995 ; 29: 1039-1948
31. Nagatsu T, Udenfriend S. Photometric assay of dopamine-β-hydroxylase activity in human blood. Clin Chem. 1972 ; 18: 980-983